ELI LILLY AND COMPANY
Scientific and Medical
Publications by Lilly
Employees
Selected 2010 Publications
C034561
10/21/2011
The scientific articles listed here are a selected list of scientific and medical journal publications
with Lilly employees as authors. URLS and Digital Object Identifiers have been included where
available. This list is representative and does not present all publications by Lilly employees. It is
provided for informational and non-promotional purposes only.
1.
Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis
Cipriani, Andrea ; Rendell, Jennifer; Geddes, John R.
Journal of Psychopharmacology. 24(12). DEC 2010. 1729-1738.
Digital Object Identifier http://dx.doi.org/10.1177/0269881109106900
2.
Integrating molecular diagnostics into anticancer drug discovery
Petak, Istvan Schwab, Richard ; Orfi, Laszlo ; Kopper, Laszlo ; Keri, Gyorgy .
Nature Reviews Drug Discovery. 9(7). JUL 2010. 523-535.
Digital Object Identifier http://dx.doi.org/10.1038/nr3135
3.
Use of Artificial Stomach-Duodenum Model for Investigation of Dosing Fluid Effect on Clinical Trial Variability
Polster, Christopher S.; Atassi, Faraj Wu, Sy-Juen; Sperry, David C.
Molecular Pharmaceutics. 7(5). SEP-OCT 2010. 1533-1538.
Digital Object Identifier http://dx.doi.org/10.1021/mp100116g
4.
pH Measurement and a Rational and Practical pH Control Strategy for High Throughput Cell Culture System
Zhou, Haiying; Purdie, Jennifer; Wang, Tongtong; Ouyang, Anli
Biotechnology Progress. 26(3). MAY-JUN 2010. 872-880.
Digital Object Identifier http://dx.doi.org/10.1002/btpr.369
5.
An early improvement threshold to predict response and remission in first-episode schizophrenia
Schennach-Wolff, R.; Seemueller, F. H. ; Mayr, A. ; Maier, W. ; Klingberg, S. ; Heuser, I. ; Klosterkoetter, J. ; Gastpar, M. ;
Haefner, H. ; Sauer, H. ; Schneider, F. ; Gaebel, W. ; Jaeger, M. ; Moeller, H. -J. ; Riedel, M. .
British Journal of Psychiatry. 196(6). JUN 2010. 460-466.
Digital Object Identifier http://dx.doi.org/10.1192/bjp.bp.109.069328
6.
The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia:
Consistency Across World Geographies and Study Designs
Novick, D.; Ascher-Svanum, H. ; Zhu, B. ; Brnabic, A. ; Stauffer, V. ; Peng, X. ; Karagianis, J. ; Perrin, E. .
Pharmacopsychiatry. 43(3). MAY 2010. 81-85.
Digital Object Identifier http://dx.doi.org/10.1055/s-0029-1242816
7.
Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
Clark PE. Valentine V. Bodie JN. Sarwat S.
Current Medical Research & Opinion. 26(7):1745-1753, 2010 Jul.
8.
Identifying women with severe angiographic coronary disease.
Kreatsoulas C. Natarajan MK. Khatun R. Velianou JL. Anand SS.
Journal of Internal Medicine. 268(1):66-74, 2010 Jul.
Identifying women with severe angiographic coronary disease.
J Intern Med 2010; 268: 66-74.
9.
Developing good scientific publishing practices: one pharmaceutical company's perspective.
Dowsett SA. Van Campen LE. Bednar LA.
Current Medical Research & Opinion. 26(6):1249-1254, 2010 Jun.
.
Page 2
10. The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia:
Consistency Across World Geographies and Study Designs.
Novick D. Ascher-Svanum H. Zhu B. Brnabic A. Stauffer V. Peng X. Karagianis J. Perrin E.
Pharmacopsychiatry. 43(3):81-85, 2010 May.
11. Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in
Patients With Agitation.
Marder SR. Sorsaburu S. Dunayevich E. Karagianis JL. Dawe IC. Falk DM. Dellva MA. Carlson JL. Cavazzoni PA.
Baker RW.
Journal of Clinical Psychiatry. 71(4):433-441, 2010 Apr.
12. All-cause treatment discontinuation for olanzapine compared to other antipsychotics in the treatment of
schizophrenia: A meta-analysis.
Soares-Weiser K., Bechard-Evans L., Lawson A.H., Davis J., Ascher-Svanum H.
Value in Health. Conference: 15th Annual International Meeting of the International Society for Pharmacoeconomics and
Outcomes Research, ISPOR 2010 Atlanta, GA United States. Conference Start: 20100515 Conference End: 20100519.
Conference Publication: (var.pagings). 13 (3 SUPPL. 3) (pp A106), 2010.
13.
Use of concentrated insulin human regular (U-500) for patients with diabetes.
Segal A.R., Brunner J.E., Burch F.T., Jackson J.A.
American Journal of Health-System Pharmacy. 67 (18) (pp 1526-1535), 2010. Date of Publication: 15 Sep 2010.
Digital Object Identifier http://dx.doi.org/10.2146/ajhp090554
14. Strategies for conducting ADME studies during lead generation in the drug discovery process.
Cramer J.W., Mattioni B.E., Savin K.A.
IDrugs. 13 (12) (pp 857-861), 2010. Date of Publication: December 2010.
15. Humalog KwikPen: An insulin-injecting pen designed for ease of use.
Schwartz S.L., Ignaut D.A., Bodie J.N.
Expert Review of Medical Devices. 7 (6) (pp 735-743), 2010.
Digital Object Identifier http://dx.doi.org/10.1586/erd.10.63
16. A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Advani A.S., Shadman M., Ali-Osman F., Barker A., Rybicki L., Kalaycio M., Sekeres M.A., De Castro C.M., Diehl L.F.,
Moore J.O., Beaven A., Copelan E., Sobecks R., Talea P., Rizzieri D.A.
Clinical Lymphoma, Myeloma and Leukemia. 10 (6) (pp 473-476), 2010.
Digital Object Identifier http://dx.doi.org/10.3816/CLML.2010.n.082
17. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in
healthy chinese and white volunteers: An open-label trial.
Small D.S., Payne C.D., Kothare P., Yuen E., Natanegara F., Teng Loh M., Jakubowski J.A., Richard Lachno D., Li Y.G.,
Winters K.J., Farid N.A., Ni L., Salazar D.E., Tomlin M., Kelly R.
Clinical Therapeutics. 32 (2) (pp 365-379), 2010
Digital Object Identifierhttp://dx.doi.org/10.1016/j.clinthera.2010.02.015
Page 3
18. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed
therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and
continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial.
Miser W.F., Arakaki R., Jiang H., Scism-Bacon J., Anderson P.W., Fahrbach J.L.
Clinical Therapeutics. 32 (5) (pp 896-908), 2010.
Digital Object Identifierhttp://dx.doi.org/10.1016/j.clinthera.2010.05.001
19. Managing diabetes during pregnancy with insulin lispro: A safe alternative to human insulin.
Edson E.J., Bracco O.L., Vambergue A., Koivisto V.
Endocrine Practice. 16 (6) (pp 1020-1027), 2010.
Digital Object Identifier http://dx.doi.org/10.4158/EP10003.RA
20. Engineering information management - Electronic project data from design through delivery.
Velen R., Naughton D., Stromgren R.
Pharmaceutical Engineering. 30 (4) (pp 70-77), 2010.
21. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
Berger M.L., Eck S., Ruberg S.J.
Journal of Clinical Oncology. 28 (20) (pp e343-e344), 2010.
Digital Object Identifier http://dx.doi.org/10.1200/JCO.2010.28.2475
22. Comparison of assay formats for drug-tolerant immunogenicity testing.
Butterfield A.M., Chain J.S., Ackermann B.L., Konrad R.J.
Bioanalysis. 2 (12) (pp 1961-1969), 2010. .
Digital Object Identifier http://dx.doi.org/10.4155/bio.10.136
23. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
Nelson D.L., Phebus L.A., Johnson K.W., Wainscott D.B., Cohen M.L., Calligaro D.O., Xu Y.-C.
Cephalalgia. 30 (10) (pp 1159-1169), 2010. Date of Publication: October 2010.
Digital Object Identifier http://dx.doi.org/10.1177/0333102410370873
24. Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating
hormone receptor 1 (MCH1-R) antagonism in Wistar rats.
Cippitelli A., Karlsson C., Shaw J.L., Thorsell A., Gehlert D.R., Heilig M.
Psychopharmacology. 211 (4) (pp 367-375), 2010.
Digital Object Identifier http://dx.doi.org/10.1007/s00213-010-1891-y
25. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a
novel object recognition test in rats.
Arnt J., Bang-Andersen B., Grayson B., Bymaster F.P., Cohen M.P., Delapp N.W., Giethlen B., Kreilgaard M., McKinzie
D.L., Neill J.C., Nelson D.L., Nielsen S.M., Poulsen M.N., Schaus J.M., Witten L.M.
International Journal of Neuropsychopharmacology. 13 (8) (pp 1021-1033), 2010.
Digital Object Identifier http://dx.doi.org/10.1017/S1461145710000659
26. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm.
Farley S., Apazoglou K., Witkin J.M., Giros B., Tzavara E.T.
Page 4
International Journal of Neuropsychopharmacology. 13 (9) (pp 1207-1218), 2010.
Digital Object Identifier http://dx.doi.org/10.1017/S1461145709991076
27. Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions
following acute ketamine challenge.
Fell M.J., Katner J.S., Johnson B.G., Khilevich A., Schkeryantz J.M., Perry K.W., Svensson K.A.
Neuropharmacology. 58 (3) (pp 632-639), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/j.neuropharm.2009.11.014
28. Activation of presynaptic alpha7 nicotinic receptors evokes an excitatory response in hippocampal CA3
neurones in anaesthetized rats: An in vivo iontophoretic study.
Huang L.-T., Sherwood J.L., Sun Y.-J., Lodge D., Wang Y.
British Journal of Pharmacology. 159 (3) (pp 554-565), 2010.
Digital Object Identifier http://dx.doi.org/10.1111/j.1476-5381.2009.00529.x
29. Disposition and metabolism of semagacestat, a -secretase inhibitor, in humans.
Yi P., Hadden C., Kulanthaivel P., Calvert N., Annes W., Brown T., Barbuch R.J., Chaudhary A., Ayan-Oshodi M.A., Ring
B.J.
Drug Metabolism and Disposition. 38 (4) (pp 554-565), 2010.
Digital Object Identifier http://dx.doi.org/10.1124/dmd.109.030841
30. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active
metabolite.
Hagihara K., Kazui M., Kurihara A., Iwabuchi H., Ishikawa M., Kobayashi H., Tanaka N., Okazaki O., Farid N.A., Ikeda T.
Drug Metabolism and Disposition. 38 (6) (pp 898-904), 2010.
Digital Object Identifier http://dx.doi.org/10.1124/dmd.110.032086
31. Patient characteristics and post-discharge clopidogrel retail pharmacy fill rates for acute coronary syndrome
patients treated by percutaneous coronary intervention or medically managed.
Winget M., Zagar A., Zhao Z., Song R., Borah B.J.
Journal of Managed Care Pharmacy. Conference: 22nd Annual Meeting and Showcase of the Academy of Managed
Care Pharmacy, AMCP San Diego, CA United States. Conference Start: 20100407 Conference End: 20100410.
Conference Publication: (var.pagings). 16 (2) (pp 162), 2010.
32. Daily average consumption and daily costs of duloxetine, Venlafaxine XR, and pregabalin among U.S.
commercially insured patients.
Able S.L., Watson P.R., Zhao Y.
Journal of Managed Care Pharmacy. Conference: 22nd Annual Meeting and Showcase of the Academy of Managed
Care Pharmacy, AMCP San Diego, CA United States. Conference Start: 20100407 Conference End: 20100410.
Conference Publication: (var.pagings). 16 (2) (pp 146-147), 2010.
33. Adherence and persistence with duloxetine and hospitalization in patients with major depressive disorder.
Liu X., Tepper P., Watson P.R.
Journal of Managed Care Pharmacy. Conference: 22nd Annual Meeting and Showcase of the Academy of Managed
Care Pharmacy, AMCP San Diego, CA United States. Conference Start: 20100407 Conference End: 20100410.
Conference Publication: (var.pagings). 16 (2) (pp 141), 2010.
Page 5
34. Socio-demographic characteristics and initial treatment decisions for patients with schizophrenia at risk of
treatment non-adherence.
Kelin K., Newton R., Simu M.I., Chuo L.-J., Escamilla R.I., Granger R.E., Ye W., Brnabic A.J.M., Montgomery W., AscherSvanum H., Karagianis J.
Schizophrenia Research. Conference: 2nd Schizophrenia International Research Society Conference, SIRS 2010
Florence Italy. Conference Start: 20100410 Conference End: 20100414. Conference Publication: (var.pagings). 117 (23) (pp 266-267), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/j.schres.2010.02.424
35. Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients
with locally advanced squamous cell carcinoma of the head and neck (scchn).
Licitra L., Bergamini C., Olmi P., Soldatenkova V., Ameryckx S., Russo F.
Annals of Oncology. Conference: 35th ESMO Congress Milan Italy. Conference Start: 20101008 Conference End:
20101012. Conference Publication: (var.pagings). 21 (pp viii320), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdq527
36. Effectiveness of taxane monotherapy (TM) and taxane combination (TC) treatment in patients with advanced
breast cancer.
Camci C., Demiray M., Szekely C., Chavez-Zamudio M.A., Kral A., Weitckus S., Soldatenkova V., Benhadji K.
Annals of Oncology. Conference: 35th ESMO Congress Milan Italy. Conference Start: 20101008 Conference End:
20101012. Conference Publication: (var.pagings). 21 (pp viii111), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdq517
37. Taxane-based treatment options for patients with HER2-positive advanced breast cancer: Results of an
observational study.
Gms M., Davidson N., Hurtado De Mendoza F., Brychta M., Donadio M., Kral A., Weitckus S., Soldatenkova V., Benhadji
K.
Annals of Oncology. Conference: 35th ESMO Congress Milan Italy. Conference Start: 20101008 Conference End:
20101012. Conference Publication: (var.pagings). 21 (pp viii103), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdq517
38. Drivers of treatment decision following first-line therapy in advanced non-small cell lung cancer.
Lasch K., Stokes J., Liepa A.M., Meldahl M., Arnett L., Basch E.
Supportive Care in Cancer. Conference: 2010 International Multinational Association of Supportive Care in Cancer,
MASCC/International Society for Oral Oncology, ISOO Symposium Vancouver, BC Canada. Conference Start: 20100624
Conference End: 20100626. Conference Publication: (var.pagings). 18 (pp S88-S89), 2010
Digital Object Identifier http://dx.doi.org/10.1007/s00520-010-0891-0
39. Disease progression modelling to quantify the effects of exenatide twice daily and once weekly formulations on
HbA1c in patients with type 2 diabetes.
Mondick J.T., Kothare P., Gastonguay M.R., Cirincione B.
Diabetologia. Conference: 46th Annual Meeting of the European Association for the Study of Diabetes, EASD 2010
Stockholm Sweden. Conference Start: 20100920 Conference End: 20100924. Conference Publication: (var.pagings). 53
(pp S335), 2010.
Digital Object Identifierhttp://dx.doi.org/10.1007/s00125-010-1872-z
Page 6
40. Effect of recombinant human growth hormone on intestinal absorption and body composition in children with
short bowel syndrome.
Goulet O., Dabbas-Tyan M., Talbotec C., Kapel N., Rosilio M., Souberbielle J.-C., Corriol O., Ricour C., Colomb V.
Journal of Parenteral and Enteral Nutrition. 34 (5) (pp 513-520), 2010.
Digital Object Identifier http://dx.doi.org/10.1177/0148607110362585
41. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival
in murine pneumococcal pneumonia.
Schouten M., Van't Veer C., Van Den Boogaard F.E., Gerlitz B., Grinnell B.W., Roelofs J.J.T.H., Levi M., Van Der Poll T.
Journal of Infectious Diseases. 202 (10) (pp 1600-1607), 2010.
Digital Object Identifier http://dx.doi.org/10.1086/656787
42. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with
metformin.
Liutkus J., Rosas Guzman J., Norwood P., Pop L., Northrup J., Cao D., Trautmann M.
Diabetes, Obesity and Metabolism. 12 (12) (pp 1058-1065), 2010
Digital Object Identifier http://dx.doi.org/10.1111/j.1463-1326.2010.01251.x
43. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): A
phase I dose-finding study.
Ranson M., Reck M., Anthoney A., Hanauske A.-R., Dean E., Melezinek I., Klingelschmitt G., Kletzl H., Blatter J., Twelves
C.
Annals of Oncology. 21 (11) (pp 2233-2239), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdq246
44. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and
prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis.
Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., Simon T., Antman E.M., Braunwald E., Sabatine M.S.
The Lancet. 376 (9749) (pp 1312-1319), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/S0140-6736%2810%2961273-1
45. Safety and resource utilization by non-small cell lung cancer histology: Results from the randomized phase III
study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with advanced nonsmall cell lung cancer.
Novello S., Pimentel F.L., Douillard J.-Y., O'Brien M., Von Pawel J., Eckardt J., Liepa A.M., Simms L., Visseren-Grul C.,
Paz-Ares L.
Journal of Thoracic Oncology. 5 (10) (pp 1602-1608), 2010.
Digital Object Identifier http://dx.doi.org/10.1097/JTO.0b013e3181eaf30f
46. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: Initiate
and progressively advance insulin therapy in type 2 diabetes.
Jain S.M., Mao X., Escalante-Pulido M., Vorokhobina N., Lopez I., Ilag L.L.
Diabetes, Obesity and Metabolism. 12 (11) (pp 967-975), 2010. Date of Publication: November 2010.
observed with PP with no between-treatment differences in overall hypoglycaemia or weight gain.
Digital Object Identifier http://dx.doi.org/10.1111/j.1463-1326.2010.01287.x
Page 7
47. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgstrom F., Strom O., Marin F., Kutahov A., Ljunggren O.
Journal of Medical Economics. 13 (3) (pp 381-392), 2010.
Digital Object Identifier http://dx.doi.org/10.3111/13696998.2010.499072
48. A review of treatment response in type 2 diabetes: Assessing the role of patient heterogeneity.
Cantrell R.A., Alatorre C.I., Davis E.J., Zarotsky V., Le Nestour E., Carter G.C., Goetz I., Paczkowski R., Sierra-Johnson
J.
Diabetes, Obesity and Metabolism. 12 (10) (pp 845-857), 2010.
Digital Object Identifier http://dx.doi.org/10.1111/j.1463-1326.2010.01248.x
49. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: A
randomized trial.
Strojek K., Shi C., Carey M.A., Jacober S.J.
Diabetes, Obesity and Metabolism. 12 (10) (pp 916-922), 2010.
Digital Object Identifier http://dx.doi.org/10.1111/j.1463-1326.2010.01257.x
50. A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium
iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs.
Swearingen C.A., Chambers M.G., Lin C., Marimuthu J., Rito C.J., Carter Q.L., Dotzlaf J., Liu C., Chandrasekhar S.,
Duffin K.L., Mitchell P.G., Durham T.B., Wiley M.R., Thirunavukkarasu K.
Osteoarthritis and Cartilage. 18 (9) (pp 1159-1166), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/j.joca.2010.02.019
51. Retrospective evaluation of cetuximab-related adverse events from claims databases-methodological concerns.
Maier S., Peltz G., Penrod J.R., Sugarman K.P
Annals of Oncology. 21 (8) (pp 1731-1732), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdq327
52. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for
treatment of type 2 diabetes (DURATION-2): A randomised trial.
Bergenstal R.M., Wysham C., MacConell L., Malloy J., Walsh B., Yan P., Wilhelm K., Malone J., Porter L.E.
The Lancet. 376 (9739) (pp 431-439), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/S0140-6736%2810%2960590-9
53. Change in student perception after a pharmaceutical industry advanced pharmacy practice experience.
Marrone C.M., Ruble G.C.
Drug Information Journal. 44 (2) (pp 131-136), 2010.
Link to the Ovid Full Text or citation:
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed9&AN=2010403158
54. Half-unit dose accuracy with HumaPen Luxura HD: an insulin pen for patients who need precise dosing.
Clark P.E., Okenfuss C.R., Campbell M.
Journal of diabetes science and technology. 4 (2) (pp 353-356), 2010.
Page 8
55. Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and
toddlers with Turner syndrome.
Davenport M.L., Roush J., Liu C., Zagar A.J., Eugster E., Travers S., Fechner P.Y., Quigley C.A.
Hormone Research in Paediatrics. 74 (1) (pp 23-32), 2010.
Digital Object Identifier http://dx.doi.org/10.1159/000313964
56. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes
(DURATION-3): an open-label randomised trial.
Diamant M., Van Gaal L., Stranks S., Northrup J., Cao D., Taylor K., Trautmann M.
The Lancet. 375 (9733) (pp 2234-2243), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/S0140-6736%2810%2960406-0
57. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
Clark P.E., Valentine V., Bodie J.N., Sarwat S.
Current Medical Research and Opinion. 26 (7) (pp 1745-1753), 2010.
Digital Object Identifier http://dx.doi.org/10.1185/03007995.2010.489028
58. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102
postmenopausal women with distal radial fractures.
Aspenberg P., Genant H.K., Johansson T., Nino A.J., See K., Krohn K., Garcia-Hernandez P.A., Recknor C.P., Einhorn
T.A., Dalsky G.P., Mitlak B.H., Fierlinger A., Lakshmanan M.C.
Journal of Bone and Mineral Research. 25 (2) (pp 404-414), 2010.
Digital Object Identifier http://dx.doi.org/10.1359/jbmr.090731
59. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: Final
analysis of a randomised trial.
Joensuu H., Sailas L., Alanko T., Sunela K., Huuhtanen R., Utriainen M., Kokko R., Bono P., Wigren T., Pyrhonen S.,
Turpeenniemi-Hujanen T., Asola R., Leinonen M., Hahka-Kemppinen M., Kellokumpu-Lehtinen P.
Annals of Oncology. 21 (5) (pp 968-973), 2010.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdp397
60. Voluntary exploratory data submissions to the US FDA and the EMA: Experience and impact.
Goodsaid F.M., Amur S., Aubrecht J., Burczynski M.E., Carl K., Catalano J., Charlab R., Close S., Cornu-Artis C., Essioux
L., Fornace A.J., Hinman L., Hong H., Hunt I., Jacobson-Kram D., Jawaid A., Laurie D., Lesko L., Li H.-H., Lindpaintner
K., Mayne J., Morrow P., Papaluca-Amati M., Robison T.W., Roth J., Schuppe-Koistinen I., Shi L., Spleiss O., Tong W.,
Truter S.L., Vonderscher J., Westelinck A., Zhang L., Zineh I.
Nature Reviews Drug Discovery. 9 (6) (pp 435-445), 2010.
Digital Object Identifier http://dx.doi.org/10.1038/nrd3116
61. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV
non-small-cell lung cancer in two phase II trials.
Zinner R.G., Novello S., Peng G., Herbst R., Obasaju C., Scagliotti G.
Clinical Lung Cancer. 11 (2) (pp 126-131), 2010.
Digital Object Identifier http://dx.doi.org/10.3816/CLC.2010.n.017
Page 9
62. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia:
Consistency across world geographies and study designs.
Novick D., Ascher-Svanum H., Zhu B., Brnabic A., Stauffer V., Peng X., Karagianis J., Perrin E.
Pharmacopsychiatry. 43 (3) (pp 81-85), 2010.
Digital Object Identifier http://dx.doi.org/10.1055/s-0029-1242816
63. Alzheimer's disease: Strategies for disease modification.
Citron M.
Nature Reviews Drug Discovery. 9 (5) (pp 387-398), 2010.
Digital Object Identifier http://dx.doi.org/10.1038/nrd2896
64. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients
with agitation.
Marder S.R., Sorsaburu S., Dunayevich E., Karagianis J.L., Dawe I.C., Falk D.M., Dellva M.A., Carlson J.L., Cavazzoni
P.A., Baker R.W.
Journal of Clinical Psychiatry. 71 (4) (pp 433-441), 2010.
Digital Object Identifier http://dx.doi.org/10.4088/JCP.08m04411gry
65. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or
alendronate.
Eastell R., Chen P., Saag K.G., Burshell A.L., Wong M., Warner M.R., Krege J.H.
Bone. 46 (4) (pp 929-934), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/j.bone.2009.12.021
66. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects
compared with healthy Caucasian subjects.
Small D.S., Kothare P., Yuen E., Lachno D.R., Li Y.G., Winters K.J., Farid N.A., Ni L., Jakubowski J.A., Salazar D.E.,
Thieu V.T., Payne C.D.
European Journal of Clinical Pharmacology. 66 (2) (pp 127-135), 2010. .
Digital Object Identifierhttp://dx.doi.org/10.1007/s00228-009-0737-1
67. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus
cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos K.N., Vansteenkiste J., Parikh P., von Pawel J., Manegold C., Martins R.G., Simms L., Sugarman K.P., VisserenGrul C., Scagliotti G.V.
Annals of Oncology. 21 (3) (pp 556-561), 2010. Article Number: mdp392.
Digital Object Identifier http://dx.doi.org/10.1093/annonc/mdp392
68. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in
healthy Chinese and white volunteers: An open-label trial.
Small D.S., Payne C.D., Kothare P., Yuen E., Natanegara F., Teng Loh M., Jakubowski J.A., Richard Lachno D., Li Y.G.,
Winters K.J., Farid N.A., Ni L., Salazar D.E., Tomlin M., Kelly R.
Clinical Therapeutics. 32 (2) (pp 365-379), 2010.
Digital Object Identifier http://dx.doi.org/10.1016/j.clinthera.2010.02.015
Page 10
69. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric
modulator with potential antipsychotic properties.
Leach K., Loiacono R.E., Felder C.C., McKinzie D.L., Mogg A., Shaw D.B., Sexton P.M., Christopoulos A.
Neuropsychopharmacology. 35 (4) (pp 855-869), 2010.
Digital Object Identifier http://dx.doi.org/10.1038/npp.2009.194
70. The nuts and bolts of subcutaneous insulin therapy in non-critical care hospital settings.
Juneja R., Foster S.A., Whiteman D., Fahrbach J.L.
Postgraduate Medicine. 122 (1) (pp 153-162), 2010.
Digital Object Identifier http://dx.doi.org/10.3810/pgm.2010.01.2109
71. Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR
therapy.
Classen S., Muth C., Debey-Pascher S., Eggle D., Beyer M., Mallmann M.R., Rudlowski C., Zander T., Polcher M., Kuhn
W., Lahn M., Schultze J.L., Staratschek-Jox A.
Pharmacogenetics and Genomics. 20 (3) (pp 147-156), 2010.
Digital Object Identifier http://dx.doi.org/10.1097/FPC.0b013e328335731c
72. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody
targeting the platelet-derived growth factor receptor alpha.
Shah G.D., Loizos N., Youssoufian H., Schwartz J.D., Rowinsky E.K.
Cancer. 116 (SUPPL. 4) (pp 1018-1026), 2010.
Digital Object Identifier http://dx.doi.org/10.1002/cncr.24788
73. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A
retrospective database analysis.
Lee L.J., Yu A.P., Johnson S.J., Birnbaum H.G., Atanasov P., Buesching D.P., Jackson J.A., Davidson J.A.
Diabetes Research and Clinical Practice. 87 (1) (pp 108-116), 2010. .
Digital Object Identifier http://dx.doi.org/10.1016/j.diabres.2009.09.023
74. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in
patients with glucocorticoid-induced osteoporosis.
Devogelaer J.-P., Adler R.A., Recknor C., See K., Warner M.R., Wong M., Krohn K.
Journal of Rheumatology. 37 (1) (pp 141-148), 2010. .
Digital Object Identifier http://dx.doi.org/10.3899/jrheum.090411
75. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed
therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and
continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial.
Miser W.F., Arakaki R., Jiang H., Scism-Bacon J., Anderson P.W., Fahrbach J.L.
Clinical Therapeutics. 32 (5) (pp 896-908), 2010. .
Digital Object Identifier http://dx.doi.org/10.1016/j.clinthera.2010.05.001
76. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: A population
pharmacokinetic model.
Lobo E.D., Robertson-Plouch C., Quinlan T., Hong Q., Bergstrom R.F.
Page 11
Pediatric Drugs. 12 (3) (pp 201-211), 2010.
Digital Object Identifier http://dx.doi.org/10.2165/11532580-000000000-00000
77. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and
after GH replacement.
Attanasio A.F., Mo D., Erfurth E.M., Tan M., Ho K.Y., Kleinberg D., Zimmermann A.G., Chanson P.
Journal of Clinical Endocrinology and Metabolism. 95 (1) (pp 74-81), 2010.
Digital Object Identifier http://dx.doi.org/10.1210/jc.2009-1326
78. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. [Review]
Cantrell RA. Alatorre CI. Davis EJ. Zarotsky V. Le Nestour E. Carter GC. Goetz I. Paczkowski R. Sierra-Johnson J.
Diabetes, Obesity & Metabolism. 12(10):845-57, 2010 Oct.
Digital Object Identifier http://dx.doi.org/10.1111/j.1463-1326.2010.01248.x
79. Strategies for conducting ADME studies during lead generation in the drug discovery process. [Review]
Cramer JW. Mattioni BE. Savin KA.
Idrugs. 13(12):857-61, 2010 Dec.
80. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and
prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL. Close SL. Wiviott SD. Shen L. Walker JR. Simon T. Antman EM. Braunwald E. Sabatine MS.
Lancet. 376(9749):1312-9, 2010 Oct 16.
81. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
Clark PE. Valentine V. Bodie JN. Sarwat S.
Current Medical Research & Opinion. 26(7):1745-53, 2010 Jul.
82. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia:
consistency across world geographies and study designs.
Novick D. Ascher-Svanum H. Zhu B. Brnabic A. Stauffer V. Peng X. Karagianis J. Perrin E.
Pharmacopsychiatry. 43(3):81-5, 2010 May.
Page 12